Biopharmaceuticals

Magellan Rx Management’s Medical Pharmacy Trend Report Unlocks the Latest Trends and Emerging Strategies to Manage Rising Medical Benefit Specialty Drug Spend

Retrieved on: 
Thursday, May 20, 2021

(NASDAQ: MGLN), released its eleventh annual Medical Pharmacy Trend ReportTM , featuring a comprehensive view of provider-administered medical benefit drug trends\xe2\x80\x94one of the largest drivers of total specialty drug spend.\nThis press release features multimedia.

Key Points: 
  • (NASDAQ: MGLN), released its eleventh annual Medical Pharmacy Trend ReportTM , featuring a comprehensive view of provider-administered medical benefit drug trends\xe2\x80\x94one of the largest drivers of total specialty drug spend.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210520005141/en/\nThrough 11 years of market evolution and claims data trends, the Report highlights how total medical benefit costs and per-member-per-month (PMPM) trends have continued to rise.
  • Since the first edition of the Report, commercial PMPM has nearly doubled.
  • These innovations have helped countless patients, while also presenting new complexities for managed care organizations and clinicians.

NTx Taps Biopharma Industry Executive Nancy Rurkowski to Join its Board of Directors

Retrieved on: 
Wednesday, May 12, 2021

b'NTx , biomanufacturing and bioinformatics company, today announced that biopharma industry veteran Nancy Rurkowski has joined its Board of Directors.\nThis press release features multimedia.

Key Points: 
  • b'NTx , biomanufacturing and bioinformatics company, today announced that biopharma industry veteran Nancy Rurkowski has joined its Board of Directors.\nThis press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20210512005356/en/\nRurkowski brings over 35 years of pharmaceutical and biologics operations experience from Bristol-Myers Squibb.
  • The company is commercializing its biomanufacturing systems NTxpress\xc2\xae, NTxscribe\xc2\xae and the bioinformatics platform, DruID, for the discovery of natural products.
  • NTx biosynthesis technology, which is built for mRNA and proteins that are made in-vitro, is completely defined as it is not dependent on cell lines.

Debut Biotech Partners with DSM to Biomanufacture High Value Natural Ingredients

Retrieved on: 
Thursday, May 6, 2021

b'SAN DIEGO, May 6, 2021 /PRNewswire-PRWeb/ --Debut Biotech, a cell-free biomanufacturing platform, today announced that they have entered into an agreement with Royal DSM ("DSM") to evaluate the Debut Biotech scalable cell-free biomanufacturing platform.

Key Points: 
  • b'SAN DIEGO, May 6, 2021 /PRNewswire-PRWeb/ --Debut Biotech, a cell-free biomanufacturing platform, today announced that they have entered into an agreement with Royal DSM ("DSM") to evaluate the Debut Biotech scalable cell-free biomanufacturing platform.
  • Debut\'s platform will be used to create natural ingredients together with DSM for use in personal health, food, and lifestyle products.\n"Biomanufacturing holds promise for the sustainable production of materials and ingredients, but the traditional cell-based fermentation approach has limitations especially for high-value specialty ingredients," said Joshua Britton, CEO of Debut Biotech.
  • By going cell-free, Debut Biotech is able to manufacture up to 1000% more than with previous methods.
  • "The biomanufacturing of natural products has the potential to produce high value ingredients that customers are increasingly demanding.

Ligand Reports First Quarter 2021 Financial Results

Retrieved on: 
Monday, May 3, 2021

b"Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2021 and provided an operating forecast and program updates.

Key Points: 
  • b"Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2021 and provided an operating forecast and program updates.
  • Royalties for the first quarter of 2021 were $7.1 million, compared with $6.6 million for the same period in 2020.
  • Adjusted net income for the first quarter of 2021 was $24.3 million, or $1.41 per diluted share, compared with $15.3 million, or $0.89 per diluted share, for the same period in 2020.
  • Progress by multiple OmniAb partners during the first quarter resulted in more than $4 million in milestone payments being earned by Ligand.

BioLife Solutions Announces Closing of Stirling Ultracold Acquisition and Expanded Partnership with Leading Global Biopharma CDMO

Retrieved on: 
Monday, May 3, 2021

Stirling will supply approximately 100 energy-efficient ULT mechanical freezers to support this customer\'s cold chain capabilities for biologics and emerging modalities.

Key Points: 
  • Stirling will supply approximately 100 energy-efficient ULT mechanical freezers to support this customer\'s cold chain capabilities for biologics and emerging modalities.
  • Dusty and the entire Stirling team continue to deliver innovative solutions and stellar support to cell and gene therapy developers and contract manufacturing companies.
  • "\nStirling Ultracold manufactures and sells environmentally sustainable ultra-low temperature (ULT) freezers for the global market.
  • For more information, please call (740) 274-7900, or visit www.StirlingUltracold.com .\nBioLife Solutions is a leading supplier of class-defining cell and gene therapy bioproduction tools and services.

New Biomanufacturing Institute BioMADE Launches April 28

Retrieved on: 
Tuesday, April 27, 2021

b"Join a live virtual event on Wednesday, April 28 to celebrate the official launch of BioMADE , a new Manufacturing Innovation Institute that is dedicated to biomanufacturing research and development.

Key Points: 
  • b"Join a live virtual event on Wednesday, April 28 to celebrate the official launch of BioMADE , a new Manufacturing Innovation Institute that is dedicated to biomanufacturing research and development.
  • \xe2\x80\x9cLaunching this new institute will catalyze the bioindustrial manufacturing industry across the U.S.
  • \xe2\x80\x9cWe look forward to funding innovative research on both technology and education and workforce development projects.
  • \xe2\x80\x9cBioMADE represents the future of manufacturing in America, and we can\xe2\x80\x99t wait to get started.\xe2\x80\x9d\n"

Matan Kicks Off Next Phase of Progress Labs™ with 532,000 SF of Spec Biomanufacturing and Research Space in Montgomery County, MD

Retrieved on: 
Tuesday, April 27, 2021

The key component of the evolution is the addition of 532,000 square feet of best-in-class biomanufacturing and life science research space in three, brand new facilities.

Key Points: 
  • The key component of the evolution is the addition of 532,000 square feet of best-in-class biomanufacturing and life science research space in three, brand new facilities.
  • "We are going to deliver three, next generation biomanufacturing and research buildings.
  • Milestone already consists of 40% research, development, and tech manufacturing users, so this is a natural evolution.
  • The timely completion of Milestone Innovation Park will help create faster access to the biomanufacturing and research space sought out by immunology companies.

Bushu Pharma's Collaboration with Suzuken Group Expands Services for Specialty Pharmaceuticals

Retrieved on: 
Tuesday, April 27, 2021

In line with this trend, the number of pharmaceutical manufacturers aiming to introduce these types of products to Japan has been increasing as well.

Key Points: 
  • In line with this trend, the number of pharmaceutical manufacturers aiming to introduce these types of products to Japan has been increasing as well.
  • Suzuken, one of the largest companies in that sector, possesses a distribution network in Japan that can support the international transportation of specialty pharmaceuticals.
  • The Cubixx specialty drug traceability system can address the need to strictly monitor and control temperature for specialty drugs.
  • Bushu Pharma\'s GTA services offering lets international pharmaceutical companies effectively import bulk products into Japan for quality inspection, labeling, packaging and distribution throughout Japan and Asia-Pacific.

Biotech Entrepreneurs Launch Agathos Biologics

Retrieved on: 
Wednesday, April 21, 2021

b'Agathos Biologics , a biotechnology company developing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy within a strong ethical and moral framework, today announced the launch of its research and development operations.

Key Points: 
  • b'Agathos Biologics , a biotechnology company developing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy within a strong ethical and moral framework, today announced the launch of its research and development operations.
  • View the full release here: https://www.businesswire.com/news/home/20210421005234/en/\nFounders of Agathos Biologics (Photo: Business Wire)\nThe company was founded by biotechnology entrepreneurs James Brown, Michael Chambers and John Ballantyne to pursue innovations in biotechnology that create value by positively impacting the health and welfare of society.
  • Prior to Aldevron Brown helped launch Regenxbio in 2008, serving as Vice President of Technical Operations until 2015.
  • \xe2\x80\x9c\xe2\x80\x99 Agathos Biologics \xe2\x80\x93 Good Science for a Better World \xe2\x80\x99 describes the company and our approach and is publicly available on our web site.\xe2\x80\x9d\nAgathos Biologics is a biotechnology company pursuing transformational science in biomanufacturing, biologic payload delivery, and cell and gene therapy.

Prime Therapeutics studies: Integrated pharmacy, medical data inform effective drug therapy management for high-cost conditions

Retrieved on: 
Wednesday, April 7, 2021

Recently, Prime analyzed integrated pharmacy and medical claims data for specialty drug use in autoimmune conditions the top cost drivers among all drug health care expenses.

Key Points: 
  • Recently, Prime analyzed integrated pharmacy and medical claims data for specialty drug use in autoimmune conditions the top cost drivers among all drug health care expenses.
  • With the drug therapies to treat autoimmune conditions being billed on both the medical and pharmacy benefits, a complete picture can be seen with integrated medical and pharmacy analytics.
  • In addition, these findings are essential to comprehensive medical and pharmacy drug benefit management that health plans are charged with providing for their members.
  • Though less than 1% of Prime's commercially insured members suffer from these conditions, the related drug treatments were approaching 20% of all drug spend through the medical and pharmacy benefit.